The Orphan Drug Act should give Jazz Pharmaceuticals the full seven years of exclusivity for its blockbuster narcolepsy drug, Xywav, says Jazz in its suit against the FDA, claiming the agency’s approval of a competitor drug, Lumryz, is unlawful.